What is the clinical evidence from this study?

Study design: Review. Population: Diabetes and cardiovascular disease. Intervention: Aspirin.

February 6, 2007European Heart JournalOpen Access

AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions

View Full Paper

Ask AI

Bookmark

Key result

Aspirin for primary cardiovascular prevention in diabetes has divergent recommendations from US and European societies due to reliance on dated trials and high uncertainty regarding its benefit-risk balance.

Why the study?

Does aspirin prevent cardiovascular disease in individuals with diabetes for primary prevention?

Population

Individuals with diabetes (primary prevention of cardiovascular disease)

Design

Review

Authors

ANAntonio NicolucciCenter for Outcomes Research and Clinical Epidemiology GBGiorgia De BerardisCenter for Outcomes Research and Clinical Epidemiology MSMichele SaccoUniversity of Verona

Discussion

Member takes

Implication

Uncertainty warrants individualized decisions over routine use; leaves open aspirin's net benefit pending contemporary trials.

Structured PICO

Does aspirin prevent cardiovascular disease in individuals with diabetes for primary prevention?

Population

Individuals with diabetes (primary prevention of cardiovascular disease)

Intervention

Aspirin

Outcome

Primary prevention of cardiovascular disease (myocardial infarction, CV death, stroke)hard clinical

There is significant divergence between US and European guidelines regarding the use of aspirin for primary prevention of cardiovascular disease in patients with diabetes, driven by reliance on dated and limited evidence.

Limitations

Existing knowledge is mainly derived from dated trials, including small numbers of patients, and hardly representing current strategies for the management of CV risk factors.
Existing knowledge is mainly derived from dated trials
Small numbers of patients in existing trials
Existing trials hardly represent current strategies for the management of CV risk factors

Cite This Study

Nicolucci et al. (2007) conducted a review in Diabetes and cardiovascular disease. Aspirin was evaluated. Aspirin for primary cardiovascular prevention in diabetes has divergent recommendations from US and European societies due to reliance on dated trials and high uncertainty regarding its benefit-risk balance.

synapsesocial.com/papers/6a696ea4a7344df3fa47ef68 https://doi.org/10.1093/eurheartj/ehm248

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Topics

AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Also Consider

Topics

Also Consider